FGFR2 Mutation is an inclusion criterion in 25 clinical trials for malignant solid tumor, of which 19 are open and 6 are closed. Of the trials that contain FGFR2 Mutation and malignant solid tumor as inclusion criteria, 7 are phase 1 (2 open), 6 are phase 1/phase 2 (5 open), 10 are phase 2 (10 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 9 clinical trials for urothelial carcinoma, of which 9 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and urothelial carcinoma as inclusion criteria, 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 6 are open and 2 are closed. Of the trials that contain FGFR2 Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 6 are phase 2 (5 open) [5].

FGFR2 Mutation is an inclusion criterion in 7 clinical trials for cholangiocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

FGFR2 Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FGFR2 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain FGFR2 Mutation and cancer as inclusion criteria, 4 are phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and glioma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for non-muscle invasive bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and non-muscle invasive bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].